Government Patent

Federal agencies own patents through a different mechanism than Bayh-Dole patents: EMPLOYEE INVENTIONS: when a federal employee (working at a national lab, agency facility, or federal research center) creates an invention: the federal agency, not the employee, owns the invention; this is the opposite of the private sector rule (where employers own employee inventions through assignment agreements); the employee's employer is the government, and the government automatically owns inventions made by federal employees within the scope of their duties; AGENCIES WITH MAJOR PATENT PORTFOLIOS: NIH (National Institutes of Health): biomedical research patents; licensed to pharmaceutical and biotech companies; DoE (Department of Energy): energy technology patents from national labs (Argonne, Oak Ridge, NREL, Lawrence Berkeley); DoD (Department of Defense): defense technology patents; military R&D; NASA: aerospace and materials technology; NIST (National Institute of Standards and Technology): measurement, standards, and materials research; USDA (Department of Agriculture): agricultural and food technology patents; INVENTIONS FROM NATIONAL LABS: DOE national laboratories (Argonne, Lawrence Livermore, Los Alamos, Sandia, etc.) are government-owned but contractor-operated (GOCOs); the contractor manages the lab but the government owns the inventions; GOCO Patent Ownership: the DOE manages the patent rights; inventions are assigned to the DOE, not the private contractor operator; EXCEPTION FOR CONTRACTOR EMPLOYEES: in some GOCO arrangements, a negotiated IP agreement may allow the operating contractor to obtain rights to inventions made by contractor employees; details vary by contract; SCALE: the US federal government holds tens of thousands of active patents; NIH alone has licensed thousands of technologies to hundreds of companies.

Federal technology transfer is governed by two key statutes: Stevenson-Wydler and FTTA: STEVENSON-WYDLER TECHNOLOGY INNOVATION ACT (1980): made technology transfer a mission of federal agencies; required agencies to actively pursue licensing of government-owned technologies; established the Office of Research and Technology Applications (ORTA) in each agency; FEDERAL TECHNOLOGY TRANSFER ACT OF 1986 (FTTA): expanded technology transfer mechanisms; enabled agencies to license federal patents; allowed CRADAs (Cooperative Research and Development Agreements); gave inventors a share of royalties; LICENSING MECHANISMS: (a) NON-EXCLUSIVE LICENSES: any qualified company may receive a non-exclusive license; standard royalty terms; no exclusivity premium; often used for broadly applicable technologies; (b) EXCLUSIVE LICENSES: available for inventions requiring substantial private investment to commercialize; requires public notice and comment period (30 days); preference for US manufacturing if exclusive license granted; higher royalty rates; term limitations; (c) PREFERRED SMALL BUSINESS LICENSING: agencies must consider whether a small business is attempting to commercialize the technology; ROYALTY SHARING WITH INVENTORS: federal inventors receive a share of royalties from licensing of their inventions; the share varies by agency but typically: 15-25% to the inventor; the remainder to the laboratory/agency; inventor's share may be capped at $150,000 per year; MARCH-IN RIGHTS: the government retains march-in rights on any exclusively licensed government-owned patent; if the licensee fails to adequately commercialize, the agency can license to another party; FOREIGN LICENSING: government-owned patents may be licensed internationally; royalties from foreign licenses are shared with the inventor.

A Cooperative Research and Development Agreement (CRADA) is the primary mechanism for collaborative R&D between federal agencies and private companies: CRADA DEFINITION: a written agreement between a federal laboratory and one or more non-federal parties (companies, universities) for collaborative R&D activities; the government and the private partner contribute resources (personnel, facilities, intellectual property) to a shared research project; AUTHORITY: 15 U.S.C. § 3710a (FTTA); all federal agencies may enter into CRADAs; WHAT A CRADA PROVIDES: (a) JOINT RESEARCH: the government's scientists work with the company's scientists on a defined research project; (b) IP RIGHTS: inventions made solely by government employees: owned by the government; inventions made solely by company employees: owned by the company; JOINT INVENTIONS: both parties contribute to the conception; co-owned; (c) LICENSE RIGHTS: the CRADA partner typically gets: first option to negotiate an exclusive license for any government-owned inventions made under the CRADA; often at predetermined royalty terms; for a limited period (typically 6 months to 1 year to exercise the option); CRADA PARTNER ADVANTAGES: advance access to government research and scientists; early rights to emerging technologies; ability to direct some research topics; reduced cost of R&D (government resources contributed); CRADA NEGOTIATION: the specific IP terms are negotiated on a CRADA-by-CRADA basis; some agencies use standard templates; key terms: field of use for the license option; term of the license; royalty rates; background IP protections; PUBLICATION RIGHTS: the government must publish or present research results; the CRADA partner typically has a review period (60-90 days) to identify inventions to be protected before publication; MATERIAL TRANSFER: CRADAs may include Material Transfer Agreements (MTAs) for research materials.

Federal agency patent licenses follow established frameworks with agency-specific variations: EXCLUSIVE LICENSE TERMS: field of use: typically limited to specific applications; prevents the licensee from locking up broad technology; term: often co-extensive with patent term; may be shorter with performance milestones; royalty structure: upfront fee (minimum); running royalty on sales; milestone payments; sublicensing fee share; diligence requirements: the licensee must actively commercialize; annual progress reports; minimum spending requirements; development milestones; failure to meet milestones = termination right for the agency; US MANUFACTURING PREFERENCE: for exclusive licenses, the licensee must agree to substantially manufacture in the US; waiver available if manufacturing in the US is not commercially feasible; NON-EXCLUSIVE LICENSE TERMS: relatively simple; standard royalty rate; no diligence requirements; no US manufacturing preference; royalty typically 1-5% of net sales depending on technology area; REACH-THROUGH ROYALTIES: some government licenses include reach-through provisions: royalty on products developed using the licensed technology even beyond the licensed patent claims; reach-through royalties are controversial and increasingly disfavored; GOVERNMENT USE LICENSE RETAINED: the government always retains a paid-up license to use the technology; § 1498 rights also apply; FOREIGN COUNTERPARTS: US government patents may have PCT or foreign national phase counterparts; licensing terms cover the US patent; foreign patents may be separately licensed; DRUG AND BIOLOGICAL PRICING: controversy over NIH-licensed drug prices; the NIH considers whether licensing terms adequately address public health needs; no specific pricing requirement under Bayh-Dole or FTTA but the government can decline to grant exclusive licenses to companies seeking excessive prices (through the public interest standard in exclusive license review).

The distinction between government-owned (agency) patents and Bayh-Dole (grantee-owned) patents has significant practical implications: OWNERSHIP: Government-owned: title held by the federal agency; licensees must deal with the agency; Bayh-Dole (grantee-owned): title held by the university or company; the agency retains march-in rights but is not the licensor; LICENSING AUTHORITY: Government-owned: the agency licenses directly; the licensing office is within the agency (NIH Office of Technology Transfer, DOE OSTI, etc.); Bayh-Dole: the grantee (university tech transfer office or company) licenses; the agency is not directly involved in licensing unless exercising march-in rights; NEGOTIATING PARTNER: Government-owned: negotiate with a federal agency; government contracting regulations apply; Federal Acquisition Regulation (FAR) influences the terms; Bayh-Dole: negotiate with a university or company tech transfer office; commercial contract terms apply; EXCLUSIVITY: both allow exclusive licensing; government-owned exclusive licenses require additional public notice and public interest evaluation; Bayh-Dole exclusive licenses: the grantee decides without prior agency approval (but is encouraged to prefer small businesses); ROYALTY DISTRIBUTION: Government-owned: inventor receives a share (typically 15-25%); remainder goes to the laboratory/agency; Bayh-Dole: the grantee sets its own royalty sharing policy; typical university split: 33% inventor, 33% department/school, 33% central administration; MARCH-IN RIGHTS: both are subject to government march-in rights; government-owned patents: agency is the rights holder, no separate march-in analysis; Bayh-Dole: the agency can invoke § 203 march-in rights against the grantee or exclusive licensee; PRACTICAL LICENSING VOLUME: NIH licenses hundreds of technologies; DOE and NASA also significant; Bayh-Dole university patenting dramatically outnumbers government-owned patenting (MIT, Stanford, Caltech tech transfer offices are major licensors).